Kyowa Hakko President Yuzuru Matsuda : Speed is Key in Growing Globally
This article was originally published in PharmAsia News
In an interview with Yakuji News, Kyowa Hakko President Yuzuru Matsuda said the company was moving faster to compete globally and achieve market leadership in antibody drugs. The antibody drug market reached ¥2,200 billion last year and is estimated to reach ¥4,500 billion by 2011. A merger with Kirin Pharma is expected to create synergy for the two companies that combine Kyowa's Potelligent technology and Kirin's KM mouse technology for creating humanized antibodies. This will boost efficiency in R&D and speed up new drug development, which Matsuda said was key for Kyowa. The company has three drugs in clinical trials: Kyowa's CCR4 antibody-KW-076, Medimmune's receptor antibody-BIW-8405, and Medarex's CD 30 antibody-MDX-1401. (Click for more-Japanese language
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.